Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt No Debt
AVMXY's Cash to Debt is ranked higher than
99% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.09 vs. AVMXY: No Debt )
AVMXY' s 10-Year Cash to Debt Range
Min: 7   Max: No Debt
Current: No Debt

Equity to Asset 0.76
AVMXY's Equity to Asset is ranked higher than
80% of the 446 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. AVMXY: 0.76 )
AVMXY' s 10-Year Equity to Asset Range
Min: 0.51   Max: 0.96
Current: 0.76

0.51
0.96
F-Score: 2
Z-Score: -13.41
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -269.40
AVMXY's Operating margin (%) is ranked lower than
53% of the 459 Companies
in the Global Medical Devices industry.

( Industry Median: 5.91 vs. AVMXY: -269.40 )
AVMXY' s 10-Year Operating margin (%) Range
Min: -1723.37   Max: -178.34
Current: -269.4

-1723.37
-178.34
Net-margin (%) -191.87
AVMXY's Net-margin (%) is ranked higher than
50% of the 459 Companies
in the Global Medical Devices industry.

( Industry Median: 4.15 vs. AVMXY: -191.87 )
AVMXY' s 10-Year Net-margin (%) Range
Min: -1614.68   Max: -57.58
Current: -191.87

-1614.68
-57.58
ROE (%) -66.43
AVMXY's ROE (%) is ranked higher than
50% of the 443 Companies
in the Global Medical Devices industry.

( Industry Median: 5.20 vs. AVMXY: -66.43 )
AVMXY' s 10-Year ROE (%) Range
Min: -107.74   Max: 3.78
Current: -66.43

-107.74
3.78
ROA (%) -53.10
AVMXY's ROA (%) is ranked higher than
52% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.77 vs. AVMXY: -53.10 )
AVMXY' s 10-Year ROA (%) Range
Min: -94.68   Max: 3.73
Current: -53.1

-94.68
3.73
ROC (Joel Greenblatt) (%) -862.87
AVMXY's ROC (Joel Greenblatt) (%) is ranked lower than
51% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 9.15 vs. AVMXY: -862.87 )
AVMXY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -33950   Max: -720.64
Current: -862.87

-33950
-720.64
Revenue Growth (3Y)(%) -30.70
AVMXY's Revenue Growth (3Y)(%) is ranked higher than
50% of the 340 Companies
in the Global Medical Devices industry.

( Industry Median: 5.00 vs. AVMXY: -30.70 )
AVMXY' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 14.5
Current: -30.7

0
14.5
EBITDA Growth (3Y)(%) 26.00
AVMXY's EBITDA Growth (3Y)(%) is ranked higher than
93% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 1.60 vs. AVMXY: 26.00 )
AVMXY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -63.8   Max: 30.1
Current: 26

-63.8
30.1
» AVMXY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with AVMXY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.00
AVMXY's P/B is ranked higher than
69% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 3.95 vs. AVMXY: 4.00 )
AVMXY' s 10-Year P/B Range
Min: 0.25   Max: 6.16
Current: 4

0.25
6.16
P/S 8.00
AVMXY's P/S is ranked higher than
59% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 3.57 vs. AVMXY: 8.00 )
AVMXY' s 10-Year P/S Range
Min: 1.75   Max: 132.5
Current: 8

1.75
132.5
EV-to-EBIT -3.10
AVMXY's EV-to-EBIT is ranked higher than
52% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 61.55 vs. AVMXY: -3.10 )
AVMXY' s 10-Year EV-to-EBIT Range
Min: -8.7   Max: 0.5
Current: -3.1

-8.7
0.5
Current Ratio 4.02
AVMXY's Current Ratio is ranked higher than
81% of the 467 Companies
in the Global Medical Devices industry.

( Industry Median: 2.79 vs. AVMXY: 4.02 )
AVMXY' s 10-Year Current Ratio Range
Min: 0.3   Max: 126.2
Current: 4.02

0.3
126.2
Quick Ratio 3.58
AVMXY's Quick Ratio is ranked higher than
82% of the 467 Companies
in the Global Medical Devices industry.

( Industry Median: 2.01 vs. AVMXY: 3.58 )
AVMXY' s 10-Year Quick Ratio Range
Min: 0.3   Max: 126.2
Current: 3.58

0.3
126.2

Valuation & Return

vs
industry
vs
history
Price/Net Cash 8.00
AVMXY's Price/Net Cash is ranked higher than
95% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. AVMXY: 8.00 )
AVMXY' s 10-Year Price/Net Cash Range
Min: 1.05   Max: 25.5
Current: 8

1.05
25.5
Price/Net Current Asset Value 8.00
AVMXY's Price/Net Current Asset Value is ranked higher than
89% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. AVMXY: 8.00 )
AVMXY' s 10-Year Price/Net Current Asset Value Range
Min: 1.05   Max: 23.18
Current: 8

1.05
23.18
Price/Tangible Book 4.00
AVMXY's Price/Tangible Book is ranked higher than
79% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 6.92 vs. AVMXY: 4.00 )
AVMXY' s 10-Year Price/Tangible Book Range
Min: 0.93   Max: 18.21
Current: 4

0.93
18.21
Price/Median PS Value 0.73
AVMXY's Price/Median PS Value is ranked higher than
90% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 1.21 vs. AVMXY: 0.73 )
AVMXY' s 10-Year Price/Median PS Value Range
Min: 0.31   Max: 12.14
Current: 0.73

0.31
12.14
Earnings Yield (Greenblatt) -32.30
AVMXY's Earnings Yield (Greenblatt) is ranked lower than
52% of the 469 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. AVMXY: -32.30 )
AVMXY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 186.2   Max: 87739.4
Current: -32.3

186.2
87739.4

Analyst Estimate

Jun15
Revenue(Mil) 4
EPS($) 0.01
EPS without NRI($) 0.01

Business Description

Industry: Medical Devices » Medical Devices
Compare: » details
Traded in other countries:AVH.Australia, GCR.Germany,
Avita Medical Ltd. manufactures & sells regenerative & respiratory medical devices. It offers tissue-engineered products for wound & skin defects, spacers for adolescent & adults, ReCell Spray-On-Skin, Funhaler for asthma & Breath-ATech, among others.
» More Articles for AVMXY

Headlines

Articles On GuruFocus.com
Avita Medical Provides NICE Guidance Recommendation Update Nov 12 2014 
Avita Medical Announces Receipt of $1.4 Million R&D Tax Incentive Nov 11 2014 

More From Other Websites
AVITA MEDICAL, LTD. Financials Dec 17 2014
Avita Medical CEO Annual General Meeting Presentation Nov 24 2014
Avita Medical Provides NICE Guidance Recommendation Update Nov 17 2014
Avita Medical Provides NICE Guidance Recommendation Update Nov 13 2014
UPDATE - Avita Medical Provides NICE Guidance Recommendation Update Nov 12 2014
Avita Medical Provides NICE Guidance Recommendation Update Nov 12 2014
Avita Medical Announces Receipt of $1.4 Million R&D Tax Incentive Nov 11 2014
Avita Medical Announces Receipt of $1.4 Million R&D Tax Incentive Nov 11 2014
Avita Medical Provides Business Update and Announces Financial Results for First Quarter Ending 30... Nov 03 2014
Avita Medical (ASX:AVH) (AVMXY) Announces Comprehensive Participation at International Society of... Oct 10 2014
Avita Medical Secures US FDA Approval to Modify ReCell(R) Clinical Burns Trial Sep 16 2014
For Avita, 'NICE' Decision In September Could Be Huge Jul 15 2014
Avita Medical Ltd (ASX:AVH) New Chairman and Board Changes Jul 01 2014
Avita Medical Presents More Positive ReCell Repigmentation Trial Results Jun 11 2014
Avita Medical Appoints New Chairman May 20 2014
ReCell® Spray-on Skin® Demonstrates Superior Results Treating Hypopigmentation in Aesthetic... May 16 2014
ReCell(R) Spray-on Skin(R) Demonstrates Superior Results Treating Hypopigmentation in Aesthetic... May 15 2014
United States Food and Drug Administration Grants an Investigational Device Exemption for... Apr 10 2014
ReCell Containing Ambient-Stored Enzyme Launched in United Kingdom and Europe Apr 08 2014
Positive Clinical And Commercial Updates From Avita Medical Mar 27 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK